If you're reading this, then odds are you already know TNI Biotech Inc. (OTCMKTS:TNIB) is an exciting biotech outfit working on a handful of immunotherapies .... drugs that induce an individual's own immune system to fight a variety of illnesses. As is the case with so many other biotech companies, however, it's what you don't know about TNIB that makes it so compelling. A great deal of what you may not have realized about TNI Biotech was published today, in the latest edition of Micro Cap Review magazine.
One of the more interesting pieces of "color" unveiled in the write-up is how and why the company began.
The name Noreen Griffin may ring a bell with current and would-be TNIB shareholders. She's the founder of the company. More than that, though, she was one of the earliest beneficiaries of the company's technology, even before TNI Biotech existed. See, as a victim of ovarian and cervical cancer looking for options when there weren't many great ones, Griffin was able to piece together a combination of LDN (low-dose naltrexone) and MENK ... the core components of the company's drug pipeline now, though again, there was no TNIB when Griffin was seeking solutions.
The treatments worked, too. But, having realized this particularly immunology was too tough for the average cancer victim to find - and create - for themselves, Griffin went on a mission to find a way to bring in all the right biotechnologies as well as all the right people under one roof to focus on creating an organization that could properly win the approval for and begin marketing these two very potent solutions. The net result of that effort is the TNI Biotech we know and love today.
The company's history isn't even the most exciting part of the Micro Cap Review write-up, however.
One of the upsides of an immunotherapy is that it can be broad-based. Where as many traditional drugs target a specific cancer or virus or bacteria, immunotherapies enhance a body's innate ability to fight all sorts of diseases. Though there are a variety of ways of enhancing that disease-fighting capability, MENK and LDN have been found to be some of the more effective, broad-based approaches of improving a patient's immune system. The end result is a drug that shows potential as a treatment for several ailments. While most TNI Biotech Inc. shareholder were aware that several diseases are in play here, for the first time ever the company has not only provided a list of all the diseases it's going to be targeting, but also a timeline for when the drugs' major milestones might be hit. Even more surprising is that it's got a couple of Phase 2 and Phase 3 items in the pipeline.
Bottom line? You may have thought you knew TNI Biotech, but of you really want to know TNIB, go to page 56 of the most recent edition of Micro Cap Review. You might be pleasantly surprised about how much you didn't know.
No comments:
Post a Comment